Jyant Technologies, Inc.

Singh also developed a novel method of targeted delivery of natural compounds and therapeutic drugs using nanotechnology to treat (prostate, breast, ovarian and lung) cancer and infectious diseases. Shlevin is a bioscience industry executive with more than 25 years of senior management experience in the development and commercialization of pharmaceuticals and diagnostics. La Terza is a serial entrepreneur and past President & CEO early stage startups, Octagen, Abeome, NeurOp, and Haplomics) and current President & CEO of Aiye. Octagen developed a FVIIII product for hemophilia A patients with inhibitors called OB1, which successfully completed Phase 2 clinical testing. JYANT Technologies' mission is to develop and deliver disruptive technologies to patients, by leveraging a strong intellectual property position and unique focus on unmet medical needs in oncology and inflammatory diseases. JYANT's patented technologies provide ground-breaking solutions to diagnosis and treat a number cancers and inflammatory diseases through the use of anti-chemokine and anti-chemokine receptor antibodies. JYANT has also developed a novel nano-compounding manufacturing methodology that allows for the targeted delivery of anti-cancer and anti-inflammatory agents. JYANT's patented approach provides a means of inhibiting the growth and metastasis of cancer cells by administering high affinity anti-chemokine antibodies.